Vazzano Joseph Walter 4

What Happened
Joseph W. Vazzano, Chief Financial Officer of Abeona Therapeutics (ABEO), sold a total of 49,338 shares in open-market transactions on June 8–9, 2026. The disposals were: 10,271 shares at $5.43 ($55,766), 13,421 shares at $5.30 ($71,188), and 25,646 shares at $5.39 (~$138,288), for aggregate proceeds of roughly $265,242. These were sales (S), not purchases.

Key Details

• Transaction dates: June 8, 2026 and June 9, 2026.
• Individual trades:
  • 10,271 shares @ $5.43 — ~$55,766
  • 13,421 shares @ $5.30 — ~$71,188
  • 25,646 shares @ $5.39 — ~$138,288
• Weighted-average price ranges reported across the multiple executions: $5.345–$5.54, $5.24–$5.47, and $5.30–$5.42 (report states weighted averages and offers to provide per-price breakdown on request).
• Footnotes: the filing says the sales were to cover tax obligations from vesting of restricted stock awards; at least one sale was executed pursuant to a Rule 10b5-1 trading plan adopted Jan 21, 2026.
• Shares owned after the transactions: not disclosed in the provided filing extract.
• Filing timeliness: Form 4 was filed on June 9, 2026 (timely with the reported transaction dates).

Context
Sales to cover tax withholding on vested awards and trades under a pre-established 10b5-1 plan are common executive transactions and are typically considered routine; they do not, by themselves, indicate a judgment about the company’s outlook.